Barchas Isaac: insider trades.
Barchas Isaac reported 10 non-derivative transactions on 4 SEC ownership filings in Q3 2026: 0 open-market purchases and 10 sales ($9.9M), across 1 company.
- Transactions
- 10
- Purchases (P)
- 0
- Sales (S)
- 10
- Companies
- 1
- Name as filed
- Barchas Isaac
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Immunome Inc. (IMNM) | Director | 10 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-08-12 | Immunome Inc. | S | 11,048 | $27.25 | 92,211 | Form 4 |
| 2026-08-11 | Immunome Inc. | S | 62,291 | $26.23 | 0 | Form 4 |
| 2026-08-10 | Immunome Inc. | S | 10,125 | $26.07 | 62,291 | Form 4 |
| 2026-08-07 | Immunome Inc. | S | 15,248 | $26.06 | 72,416 | Form 4 |
| 2026-08-06 | Immunome Inc. | S | 20,840 | $26.06 | 87,664 | Form 4 |
| 2026-07-07 | Immunome Inc. | S | 16,906 | $24.2 | 108,504 | Form 4 |
| 2026-07-06 | Immunome Inc. | S | 83,094 | $24.11 | 125,410 | Form 4 |
| 2026-07-02 | Immunome Inc. | S | 75,665 | $22.35 | 232,839 | Form 4 |
| 2026-07-02 | Immunome Inc. | S | 24,335 | $23.33 | 208,504 | Form 4 |
| 2026-06-30 | Immunome Inc. | S | 101,050 | $21.12 | 308,504 | Form 4 |
Questions
What stock did Barchas Isaac buy or sell?
Barchas Isaac reported 10 non-derivative transactions on 4 SEC ownership filings in Q3 2026: 0 open-market purchases and 10 sales ($9.9M), across 1 company.
Is Barchas Isaac the same person as other filers with this name?
This page covers SEC CIK 1808343 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/barchas-isaac-1808343.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.